

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

BIO KEY INTERNATIONAL INC
Form 10QSB
August 16, 2004

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the quarterly period ended JUNE 30, 2004

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the Transition Period from _____ to _____

Commission file number 1-13463

BIO-KEY INTERNATIONAL, INC.

(EXACT NAME OF SMALL BUSINESS ISSUER AS SPECIFIED IN ITS CHARTER)

MINNESOTA

(State or Other Jurisdiction of
Incorporation of Organization)

41-1741861

(IRS Employer
Identification Number)

1285 CORPORATE CENTER DRIVE
SUITE # 175, EAGAN, MN 55121

(Address of Principal Executive Offices)

(651) 687-0414

(Issuer's Telephone Number)

Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

Yes No

APPLICABLE ONLY TO ISSUERS INVOLVED IN
BANKRUPTCY PROCEEDINGS DURING THE
PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required
to be filed by Section 12, 13 or 15(d) of the Exchange Act after the
distribution of securities under a plan confirmed by a court.

Yes No

APPLICABLE ONLY TO CORPORATE ISSUERS

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: There were 38,430,829 issued and outstanding shares of the registrant's common stock, par value \$.01 per share, as of August 12, 2004.

Transitional Small Business Disclosure Format (check one): Yes [] No [X]

BIO-KEY INTERNATIONAL, INC. INDEX

PART I. FINANCIAL INFORMATION

Item 1 - Consolidated Financial Statements

Balance sheets as of December 31, 2003, and June 30, 2004

(unaudited)

Statements of operations for the three and six months ended

June 30, 2004 and 2003 (unaudited)

Statements of cash flows for the six months ended June 30, 2004 and 2003

(unaudited)

Notes to consolidated financial statements

Item 2 - Management's Discussion and Analysis

Item 3 - Controls and Procedures

PART II. OTHER INFORMATION

Item 2 - Change in Securities and Small Business

Item 6 - Exhibits and Reports on Form 8-K.

PART I
FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BIO-key International, Inc.
and Subsidiary
CONSOLIDATED BALANCE SHEETS

	December 31, 2003	June 30, 2004
	-----	-----
ASSETS		(Unaudited)
CURRENT ASSETS		
Cash and cash equivalents	\$ 1,012,790	\$ 3,837,147
Receivables		
Trade, less allowance for doubtful accounts		
of \$2,000 and \$6,000, respectively	409,803	1,188,560
Subscription	--	50,000
Advances to shareholders and other	--	154,515
Inventory	65,857	36,910
Prepaid expenses	165,929	71,697
	-----	-----
Total current assets	1,654,379	5,338,829
EQUIPMENT AND FURNITURE AND FIXTURES - at cost, less accumulated depreciation	60,157	127,536
OTHER ASSETS		
Intangible assets - net of amortization	--	4,593,692
Marketable debt securities	--	5,887,500
Other	150,206	115,377
	-----	-----
	\$ 1,864,742	\$ 16,062,934
	=====	=====
LIABILITIES AND STOCKHOLDERS' DEFICIT		
CURRENT LIABILITIES		
Advances from shareholders	\$ 34,030	\$ 22,944
Accounts payable	351,742	550,973
Accrued liabilities	173,736	292,944

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

Deferred revenue	10,000	226,235
	-----	-----
Total current liabilities	569,508	1,093,096
LONG-TERM OBLIGATIONS	10,431,223	--
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS' EQUITY (DEFICIT)		
Preferred stock - authorized, 5,000,000 shares of \$.01 par value (liquidation preference of \$100 per share):		
Series B 9% Convertible; issued and outstanding, 4,180 as of December 31,2003	42	--
Series C 7% Convertible; issued and outstanding, 75,682 shares as of June 30, 2004	--	757
Common stock - authorized, 60,000,000 shares of \$.01 par value; issued and outstanding, 21,222,889 and 38,430,829 shares, respectively	212,229	384,308
Additional contributed capital	18,327,992	44,559,202
Deficit	(27,676,252)	(29,974,429)
	-----	-----
	(9,135,989)	14,969,838
	-----	-----
	\$ 1,864,742	\$ 16,062,934
	=====	=====

See accompanying notes to financial statements.

1

BIO-key International, Inc.
and Subsidiary
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

	Three months ended June 30,		Six ended
	2003	2004	2003
	-----	-----	-----
Revenues			
Product sales	\$ 5,305	\$ 111,118	\$ 6,830
Licensing fees	5,000	304,557	30,000
Technical support and other services	2,715	103,439	3,694
	-----	-----	-----

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

	13,020	519,114	40,524
Costs and other expenses			
Cost of product sales	3,304	94,889	5,697
Selling, general and administrative	468,947	1,346,442	1,037,447
Research, development and engineering	253,770	351,814	474,876
	<u>726,021</u>	<u>1,793,145</u>	<u>1,518,020</u>
Operating loss	(713,001)	(1,274,031)	(1,477,496)
Other income (deductions)			
Interest expense	(302,910)	(852)	(594,255)
Sundry	426	14,175	980
	<u>(302,484)</u>	<u>13,323</u>	<u>(593,275)</u>
NET LOSS	<u>\$ (1,015,485)</u>	<u>\$ (1,260,708)</u>	<u>\$ (2,070,771)</u>
Basic and diluted loss to common stockholders			
Net loss	\$ (1,015,485)	\$ (1,260,708)	\$ (2,070,771)
Convertible preferred stock dividends and accretion	--	(153,150)	--
Loss applicable to common stockholders	<u>\$ (1,015,485)</u>	<u>\$ (1,413,858)</u>	<u>\$ (2,070,771)</u>
Basic and diluted loss per common share			
Net loss	\$ (.07)	\$ (.03)	\$ (.14)
Convertible preferred stock dividends and accretion	--	(.01)	--
Loss applicable per common share	<u>\$ (.07)</u>	<u>\$ (.04)</u>	<u>\$ (.14)</u>
Weighted average number of common shares outstanding	<u>14,886,809</u>	<u>37,693,849</u>	<u>14,632,108</u>

See accompanying notes to financial statements

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

	2003	2004
	-----	-----
Cash flows from operating activities		
Net loss	\$ (2,070,771)	\$ (2,172,586)
Adjustments to reconcile		
net loss to net cash used		
in operating activities:		
Depreciation	--	17,015
Amortization		
Intangible assets	--	108,329
Discounts on convertible		
debt related to warrants and		
beneficial conversion features	277,092	--
Allowance for bad debts	--	4,000
Options and warrants issued for		
services and other	156,000	--
Change in assets and liabilities:		
Accounts receivable	60,570	(664,478)
Inventory	--	28,947
Prepaid expenses and other	(42,633)	155,351
Accounts payable	(22,310)	(114,080)
Accrued liabilities	335,145	254,508
Deferred revenue	--	75,747
	-----	-----
Net cash used in operations	(1,306,907)	(2,307,247)
Cash flows from investing activities		
Capital expenditures	--	(79,089)
Investments	--	(5,887,500)
Acquisition	--	(498,937)
Subscription	--	(50,000)
Other	(8,075)	(25,739)
	-----	-----
Net cash used in		
investing activities	(8,075)	(6,541,265)
Cash flows from financing activities		
Issuance of convertible debentures	1,553,000	1,000,000
Repayment of long-term notes	--	(400,000)
Net advances from shareholders	--	(44,246)
Sale of common stock	--	11,248,803
Repurchase of warrants	--	(100,000)
Other	--	(31,688)
	-----	-----
Net cash provided by		
financing activities	1,553,000	11,672,869
	-----	-----
Net increase in cash and		
cash equivalents	238,018	2,824,357
Cash and cash equivalents,		
beginning of period	16,748	1,012,790
	-----	-----
Cash and cash equivalents,		
end of period	\$ 254,766	\$ 3,837,147
	=====	=====

See accompanying notes to financial statements.

BIO-key International, Inc.
and Subsidiary
NOTES TO FINANCIAL STATEMENTS

December 31, 2003, and June 30, 2004
(Unaudited)

1. Unaudited Statements

The accompanying unaudited interim consolidated financial statements include the accounts of BIO-key International, Inc. and their wholly owned subsidiary (collectively, the Company) and are stated in conformity with accounting principles generally accepted in the United States, pursuant to the rules and regulations of the Securities and Exchange Commission. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Significant intercompany accounts and transactions have been eliminated in consolidation.

In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the financial position and the results of its operations and cash flows for the periods presented. It is suggested that these interim consolidated financial statements are read in conjunction with the financial statements and the related notes thereto included in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2003.

2. Liquidity and Capital Resource Matters

Broad commercial acceptance of the Company's technology is critical to the Company's success and ability to generate revenues. The Company has accumulated losses during the last two years and through the second quarter of 2004 of approximately (\$10,019,000) of which approximately (\$2,173,000) was incurred during 2004. As of June 30, 2004 stockholders' equity was approximately \$14,970,000.

On March 31, 2004 substantial doubt about the Company's ability to continue as a going concern was alleviated when 8,888,928 shares of the Company's common stock were sold for approximately \$12,000,000 in gross proceeds.

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States, which contemplate continuation of the Company as a going concern. The matters described in the preceding paragraph removed substantial doubt about the Company's ability to continue as a going concern.

3. Loss per Common Share

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

Basic loss per share is calculated by dividing the net loss attributable to common stockholders by the number of weighted average common shares outstanding. Diluted earnings per share are calculated by dividing the net loss attributable to common stockholders by the weighted average common shares, and when dilutive, by including options, warrants and convertible securities outstanding using the treasury stock method. There was no difference between basic and diluted loss per share for all periods presented, because the impact of including options, warrants and convertible securities would be antidilutive.

4. Marketable Debt Securities

Debt and equity securities designated as available-for-sale, whose fair values are readily determinable, are carried at fair value with unrealized gains or losses included as a component of accumulated other comprehensive income, net of applicable taxes. Debt and equity securities classified as trading securities are carried at fair value with unrealized gains or losses included in income. Debt securities that are expected to be held-to-maturity are carried at amortized cost. Individual securities classified as either available-for-sale or held-to-maturity are reduced to net realizable value by a charge to income for other than temporary declines in fair value. Realized gains and losses are determined on the average cost method and are reflected in income. As of June 30, 2004, the Company's investments are all classified as held-to-maturity securities and are carried at amortized cost of \$5,887,500. The fair market value of these investments as of June 30, 2004 were \$5,734,710, resulting in unrealized losses of \$152,790.

5. Acquisition of Public Safety Group, Inc.

On March 30, 2004, we acquired all of the outstanding capital stock of Public Safety Group, Inc. (PSG), a privately-held leader in wireless solutions for law enforcement and public safety markets based in Winter Park, Florida. The acquisition was completed pursuant to the terms of an Agreement and Plan of Merger (the Merger Agreement) by and among the Company, BIO-Key Acquisition Corp., a wholly-owned subsidiary of the Company, PSG and all of the shareholders of PSG. As a result of this transaction PSG became a wholly-owned subsidiary of the Company and now constitutes a division of our business specializing in the law enforcement and public safety markets (the Public Safety Division). The business combination will be accounted for using the purchase method.

Pursuant to the Merger Agreement, we purchased all of the outstanding capital stock of PSG from the former shareholders of PSG in exchange for an aggregate of 2,416,108 shares of our common stock issued to the former shareholders of PSG, 6,000 shares of our common stock issued to Harward Investments, Inc. (Harward) pursuant to an arrangement involving the discharge of certain outstanding debt obligations of PSG to Harward as of March 30, 2004, \$500,000 in cash, and our assumption of \$600,000 in aggregate net liabilities of PSG. The Merger Agreement provides that any liability or obligation of PSG in Excess of such \$600,000 limitation, whether arising before or after the effective date of the merger, will be solely the responsibility of the former shareholders of PSG. Additional earnout consideration, determined as a proportion of revenues attained by the Public Safety Division over fiscal years 2004 and 2005, may be paid to the former shareholders of PSG. The Company will make payments of such additional consideration on

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

the last day of the month following each month in which the Public Safety Division achieves specified revenue milestones during fiscal years 2004 and 2005. Such payments will be made in cash, unless the aggregate amount of earnout consideration exceeds sixty percent (60%) of the aggregate consideration paid by the Company in the merger transaction. Any such excess amounts will be paid in shares of our common stock priced as of two (2) days prior to the date on which any earnout payment becomes due. In connection with this acquisition, three former employees of PSG, who were also shareholders of PSG, entered into two-year employment agreements with the Company to serve within the Public Safety Division.

5

The 2,416,108 shares issued to the PSG shareholders (the Merger Shares) are subject to escrow provisions contained in the Merger Agreement and a related escrow agreement, which provide for periodic releases of the shares from escrow on a schedule determined by the revenues achieved by the Public Safety Division during fiscal years 2004 and 2005. The owners of such escrowed shares, however, will continue to enjoy all the rights and privileges attributable to the shares, including, without limitation, the right to vote and receive dividends. The principal terms of the escrow arrangement are as follows:

- o One-twelfth (1/12) of the Merger Shares are held in escrow for the purpose of securing certain prior obligations of PSG to Harward and will be released upon the effectiveness of this registration statement to the shareholders of PSG and Harward.
- o The remaining eleven-twelfths (11/12) of the Merger Shares will be released to the former shareholders of PSG at quarterly intervals, on a distribution schedule determined by the revenues achieved by the Public Safety Division during 2004. According to the distribution schedule, all of the Merger Shares will be released as early as June 30, 2006 but no later than December 31, 2007.
- o Of the remaining eleven-twelfths (11/12) of the Merger Shares, those shares owned by former employees of PSG who became our employees by virtue of the merger transaction are subject to repurchase by us under certain circumstances involving the termination of such employee's employment. Shares remaining in escrow may also be used to fund identification obligations of the former PSG shareholders pursuant to the Merger Agreement.

6

A summary of the estimated fair value of the net assets acquired and liabilities assumed, pertaining to the purchased entity is as follows:

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

Current assets	\$ 133,369
Goodwill	2,535,445
Copyrighted software	1,181,429
Marketing agreements	605,340
Trademarks	379,807
Other assets	5,857

Total assets acquired	4,841,247
Current liabilities	(332,307)
Long-term liabilities	(400,000)

Purchase Price	\$ 4,108,940
	=====

The Company acquired all of the issued and outstanding capital stock of PSG, effective March 30, 2004. The following pro forma financial data, unaudited, reflects revenue, loss from continuing operations, net loss and loss applicable per common share of the Company for the three month periods ended June 30, 2004 and 2003, and six month periods ended June 30, 2003 and 2004 as though the transaction occurred as of January 1, 2003 and 2004.

	Three months ended June 30,		Six months ended June 30,	
	2003	2004	2003	2004
	-----	-----	-----	-----
Revenue	\$ 271,968	\$ 519,114	\$ 596,079	\$ 1,015,09
Loss from continued operations	(836,466)	(1,260,708)	(1,811,409)	(2,187,25
Net Loss	(836,466)	(1,260,708)	(1,811,409)	(2,187,25
Loss applicable per common share	\$ (0.06)	\$ (0.03)	\$ (0.12)	\$ (0.0

6. Prepaid Expenses

	December 31, 2003	June 30, 2004
	-----	-----
Consulting fees	\$ 90,000	\$ --
Insurance	42,181	63,482
Other	33,748	8,215
	-----	-----
	\$165,929	\$ 71,697
	=====	=====

In October 2003, the Company entered into a twelve-month consulting agreement with a financial advisory services company. The terms of the consulting agreement required \$108,000 to be paid in fees over the term of the agreement. The consulting fees were charged to operations during the first quarter of 2004 as the consulting services were provided.

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

7. Equipment and Furniture and Fixtures

	December 31, 2003	June 30, 2004
	-----	-----
Equipment	\$ 66,543	\$138,151
Furniture and fixtures	36,550	45,628
Other	--	3,708
	-----	-----
	103,093	187,487
Less accumulated depreciation	42,936	59,951
	-----	-----
	\$ 60,157	\$127,536
	=====	=====

8. Other Assets

	December 31, 2003	June 30, 2004
	-----	-----
Copyrighted software	\$ --	\$1,181,429
Marketing agreements	--	605,340
Trademarks	--	379,807
	-----	-----
	--	2,166,576
Less accumulated amortization	--	108,329
	-----	-----
	--	2,058,247
Goodwill	--	2,535,445
	-----	-----
	\$ --	\$4,593,692
	=====	=====

8

Deferred Offering Costs

In March 2002, the Company engaged an investment banking firm to advise the Company regarding raising additional capital through the potential future issuance of the Company's equity, debt or convertible securities. The Company paid a nonrefundable retainer fee of \$50,000, out of pocket expenses of \$14,900 and granted a four year warrant to purchase 25,000 shares of the Company's common stock at an exercise price of \$1.00 per share. The estimated value of the warrant is \$17,000. These deferred costs were charged to operations in the quarter ended March 31, 2004, when this engagement terminated.

Impairment of Goodwill

The Company has adopted SFAS No. 142. In accordance with the adoption of this standard, the Company has not amortized goodwill. As required under SFAS No. 142, the Company performed an assessment of the carrying value of goodwill using a number of criteria, including the value of

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

the overall enterprise, and as of June 30, 2004, the Company believes no material impairment exists. Future impairment charges from existing operations or other acquisitions, if any, will be reflected as an operating expense in the statement of operations.

9. Accrued Liabilities

	December 31, 2003 -----	June 30, 2004 -----
Compensation	\$167,859	\$219,401
Payroll taxes	--	61,742
Other	5,877	11,801
	-----	-----
	\$173,776	\$292,944
	=====	=====

10. Note Payable

Pursuant to the Merger Agreement, the Company assumed a maximum of \$600,000 in aggregate net liabilities of PSG, which included a note payable of \$400,000. This note was subsequently paid off in April 2004.

11. Long-term Obligations

Between January 4, 2004, and March 29, 2004 as part of the Company's January 2003 amended funding transaction with an investor group (the Investor), the Investor has provided additional financing of \$1,000,000 (the Funding Agreement) in incremental monthly installments.

9

On March 30, 2004 the Company issued 18,275 shares of series C convertible preferred stock to the Investor in exchange for the cancellation of \$1,770,500 principal amount of outstanding convertible promissory notes and \$49,963 of accrued interest due thereunder.

12. Stockholders Equity

Common Stock

On March 31, 2004, the Company entered into a securities purchase agreement with certain institutional and accredited investors pursuant to which the Company issued and sold an aggregate of 8,888,928 shares of common stock and warrants to purchase an aggregate of 4,444,464 shares of common stock. The investors paid an aggregate purchase price of \$1.35 for each share of common stock and warrant to purchase 0.5 of a share of common stock, resulting in gross proceeds of approximately \$12,000,000. In connection with the securities purchase agreement, the Investor paid for a portion of their purchased stock and warrants by canceling \$347,500 of outstanding debt. The remaining aggregate

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

proceeds of \$11,248,803, net of offering costs totaling \$403,700, were held in escrow until April 2004. During March 2004, additional out of pocket offering costs of \$14,397 were accrued by the Company.

The Warrants may be exercised at any time prior to the Fifth anniversary of the effective date of this registration statement at an exercise price of \$1.755 per share. Each Warrant contains anti-dilution protection, which provides that if at any time on or prior to March 31, 2005, we issue any of our common stock or rights, options, warrants or other securities or debt bearing a right to acquire our common stock at a price less than the then-applicable exercise price of such Warrant, such exercise price will be automatically reduced to such lower price. Fifty percent (50%) of any unexercised portions of the Warrants are callable by the Company if the volume weighted average trading price per share of our common stock exceeds \$4.3875 per share for ten (10) consecutive trading days and the Warrants have not been exercised after forty-five (45) days' prior notice from the Company.

Under the Purchase Agreement, in the event that (i) this registration statement is not filed on or prior to April 30, 2004 or declared effective on or prior to July 14, 2004, (ii) after the effectiveness of this registration statement, an investor is not permitted to sell its securities hereunder (or any subsequent registration statement filed in replacement hereof) for any reason for five (5) or more trading days (whether or not consecutive), (iii) after the effectiveness of this registration statement, any securities covered hereunder are not listed on an eligible trading market or (iv) our common stock is not listed or quoted, or is suspended from trading, on an eligible trading market for a period of three (3) trading days (whether or not consecutive), the Company will be required to pay a cash amount to the investors equal to one percent (1%) of the aggregate purchase price paid by the investors pursuant to the Purchase Agreement for the first month that such event occurs and one percent (1%) for each month thereafter in which such event remains uncured, in each case prorated for any partial month. If the Company fails to make any such payment in a timely manner, such payment shall bear interest at the rate of one percent (1%) per month (prorated for partial months) until paid in full.

10

Series B Convertible Preferred Stock Dividends

On March 30, 2004 the Investor converted the remaining 4,180 shares of Series B 9% convertible preferred stock and \$107,693 of dividends and accrued interest thereon into 5,257 share of the Company's series C preferred stock. All of the Company's series C preferred stock is convertible into shares of the Company's common stock.

Series C Convertible Preferred Stock Dividends

The Company's series C preferred stock accrues dividends at 7% payable semi-annually on June 15 and December 15 and on such date that the preferred stockholder elects to convert preferred stock to common

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

stock. As of June 30, 2004 approximately \$135,000 cumulative dividends had been earned on the Series C preferred stock. All of the Company's series C preferred stock is convertible into shares of the Company's common stock.

Options and Warrants

The following summarizes option and warrant activity since December 31, 2003:

	Number of Shares			
	1996 Plan	1999 Plan	Non- Plan	Warrants
	-----	-----	-----	-----
Balance, December 31, 2003	487,380	1,176,669	3,268,000	5,394,682
Granted	--	--	75,000	4,444,464
Cancelled/Expired	(5,000)	--	--	(25,000)
	-----	-----	-----	-----
Balance, March 31, 2004	482,380	1,176,669	3,343,000	9,814,146
Granted	--	--	235,000	--
Cancelled/Expired	--	--	--	(531,250)
Exercised	--	--	--	(400,000)
	-----	-----	-----	-----
Balance, June 30, 2004	482,380	1,176,669	3,578,000	8,882,896
	=====	=====	=====	=====
Available for future grants, June 30, 2004	174,620	629,588	--	--
	=====	=====	=====	=====

11

Proforma Compensation Disclosure

In December 2002, the Financial Accounting Standards Board (FASB) issued SFASB No. 148, Accounting for Stock-Based Compensation-Transition and Disclosure. SFAS No. 148 amends SFAS No. 123, Accounting for Stock-Based Compensation, to provide alternative methods of transition for a voluntary charge to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS No. 148 requires expanded and more prominent disclosure in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method on reported results.

The Company has not adopted a method under SFAS No. 148 to expense stock options but rather continues to apply the recognition and measurement provisions of APB Opinion No.25, Accounting for Stock issued to Employees, and related interpretations in accounting for those plans. No stock-based employee compensation expense for options is reflected in net income for the fiscal periods presented as all

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

options granted under those plans had an exercise price equal to or lower than the market price of the underlying common stock at the date of grant.

If compensation expense for the stock options granted had been determined based on the fair value at the grant dates consistent with the method of SFAS No. 123, the Company's proforma net loss and proforma loss per share would have been as follows:

	Three Months Ended June 30, 2003	2004	Six Months 2003
	-----	-----	-----
Net loss			
As reported	(1,015,485)	(1,260,708)	(2,070,771)
Proforma	(1,049,235)	(1,327,708)	(2,138,271)
Loss applicable to common Stockholders			
As reported	(1,015,485)	(1,413,858)	(2,070,771)
Proforma	(1,049,235)	(1,480,858)	(2,138,271)
Basic and diluted loss per common share			
As reported	(.07)	(.04)	(.14)
Proforma	(.07)	(.04)	(.15)

13. Legal Proceedings

In June 2003, PSG, our recently-acquired subsidiary, was named as a defendant in a civil action initiated in the Superior Court Department in Hampden County, Commonwealth of Massachusetts by The Vince Group, Inc. ("TVG"). The case has since been removed to the United States District Court for the District of Massachusetts at the request of the Parties. The complaint claims that PSG is obligated to pay a percentage of certain of its revenues to TVG in consideration for a strategic

12

business introduction allegedly made by an agent of TVG. PSG has denied the allegations and filed an answer in the litigation, and as of the date of this report the outcome of the litigation is pending. The claim is for an unspecified amount including actual damages, interest, and attorney's fees. Management believes that the claim is without merit and will be settled out of court for an amount that will not have a material adverse affect on our business, financial condition or operating results.

14. Events Occurring Subsequent to June 30, 2004

In a cashless exchange in July 2004, the Company issued 251,000 shares of common stock in exchange for the cancellation of warrants valued at \$96,183.

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

In July 2004, the Company provided an employee of the Company a seven-year option to purchase 75,000 shares of the Company's common stock at an exercise price of \$1.35 per share. The option vests in three annual installments commencing July 1, 2005.

In July 2004, the Company issued five-year warrants to purchase an aggregate of 150,000 shares of common stock at an exercise price of \$.97 per share to certain consultants. The warrants shall vest as follows: 50,000 shares immediately, 75,000 shares on July 15, 2005 and 25,000 shares on July 15, 2006.

On August 16, 2004, the Company entered into a definitive agreement with Aether Systems, Inc. ("Aether") to purchase its Mobile Government Division for \$10 million in cash. It is anticipated that \$4.5 million in net working capital will be included in the assets and liabilities being conveyed, and that the acquisition will be financed using the Company's existing cash resources and new debt. In addition to the cash purchase price, the Company will either replace or secure the release of up to \$10.75 million of credit support arrangements that Aether currently has in place for its Mobile Government Division. Aether has agreed to accept a subordinated, secured note from the Company for up to \$8 million of this credit support if the Company cannot arrange to replace or release all of it by closing. The closing is expected to occur on or about September 30, 2004, and is subject to customary closing conditions.

15. Supplementary Disclosures of Cash Flow Information

	Six Months Ended June 30,	
	2003	2004
Cash paid for:		
Interest	\$ --	\$ 1,857
Noncash Financing Activities:		
Conversion of convertible debentures, bridge notes, and accrued interest into common stock	--	2,864,293
Issuance of Series C preferred stock in exchange for Series B preferred stock and cumulative dividends in arrears, thereon	--	525,668
Issuance of Series C preferred stock in exchange for debt	--	8,702,463
Issuance of common stock in exchange for warrants	--	3,039
Issuance of common stock in exchange for Series A, Series B and Series C preferred stock and cumulative dividends in arrears thereon	54,914	22,372

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

Issuance of common stock in
conjunction with the PSG acquisition

--

3,608,940

13

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS

CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS

The information contained in this Report on Form 10-QSB and in other public statements by the Company and Company officers include or may contain certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange of 1934. All statements other than statements of historical facts contained in this Report on Form 10-QSB, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words "anticipate," "believe," "estimate," "will," "may," "future," "plan," "intend" and "expect" and similar expressions generally identify forward-looking statements. Although we believe that our plans, intentions and expectations reflected in the forward-looking statements are reasonable, we cannot be sure that they will be achieved. Actual results may differ materially from the forward-looking statements contained herein due to a number of factors. Many of these factors are set forth in the Company's Registration Statement on Form SB-2 and under the caption "Risk Factors" and other filings with the Securities and Exchange Commission. These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, presently or in the future. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

OVERVIEW

The following should be read in conjunction with the consolidated financial statements of the Company included elsewhere herein.

We develop and market proprietary fingerprint identification biometric technology and software solutions. We pioneered the development of automated, finger identification technology that can be used without the aid of non-automated methods of identification such as a personal identification, password, token, smart card, ID card, credit card, passport, driver license or other form of possession or knowledge based identification. This advanced BIO-key(TM) identification technology improves both the accuracy and speed of finger-based biometrics and is the only finger identification algorithm that has been certified by the International Computer Security Association.

Since our inception in 1993, we have spent substantial time and effort in completing the development of what we believe is the most discriminating and effective fingerprint biometric technology available. During the past two years, our focus has shifted to marketing and selling this technology. We have built a direct sales force of professionals with substantial experience in selling technology solutions to government and corporate customers. We expect to continue to add additional qualified personnel during the remainder of 2004.

During 2003 and the first two quarters of 2004, we entered into a number of licensing and development agreements. Certain of these arrangements

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

have resulted in our technology being used in commercial applications on a run time basis and we are beginning to generate recurring revenue. We will continue

14

to focus a substantial amount of resources on our sales and marketing efforts and expect revenues to increase during 2004. Our primary objective in 2004 is to generate revenue and increase the recognition, use and acceptance of our technology in the market. To accomplish this, all sales efforts are focused on moving evaluation and development relationships to run time license arrangements as quickly as possible. We continue to see increases in qualified leads resulting in evaluation licenses and run time licenses. Our biggest challenge is obtaining human resources to pursue and follow up on opportunities available to us.

Although recent security concerns relating to the identification of individuals has increased interest in biometrics generally, it has yet to gain widespread commercial acceptance. We continue to see increasing acceptance of biometric technology and believe the market for our technology is large enough for us to become a successful revenue generating company. Continued concerns regarding security and increased corporate spending on technology are key external conditions which may affect our ability to execute our business plan.

On March 30, 2004, we acquired all of the outstanding capital stock of Public Safety Group, Inc. ("PSG"), a privately-held provider of wireless solutions for law enforcement and public safety markets based in Winter Park, Florida. PSG's primary technology is a software solution that provides police officers and other security personnel instantaneous access to criminal, civil and private database information in a wireless environment. PocketCop(C) is a handheld application that allows law enforcement officers to access state and federal databases over the wireless network for PalmOS, Windows CE and PocketPC. With the use of a portable wireless handheld device and PocketCop(C) application software, an authorized user can access suspect information.

We market and sell our PocketCop(C) solution primarily to state and local law enforcement agencies throughout the United States. We are establishing a strong customer base and expect continued growth in this division particularly in the current environment of heightened security concerns. We believe there is a substantial market opportunity to integrate our VST(TM) and WEB-key(TM) biometric technologies with the PSG mobile solution. The integration will provide us with the ability to offer a unique wireless solution and the opportunity to provide a meaningful upgrade to all existing customers of PSG. We expect to complete the integration of these technologies during the third quarter of 2004. In that regard we recently entered into an agreement comprised of an asset purchase of the Aether Mobil Government Division contingent upon completion subject to a number of standard closing conditions.

As more fully described in our Proxy Statement filed with the Securities and Exchange Commission, we are actively pursuing strategic acquisitions that are expected to be accretive to operating results. To enable us to respond rapidly to acquisition opportunities, and to meet other future needs that could arise, we are seeking shareholder approval to raise the number of shares we are authorized to issue from 60 million to 85 million.

On March 31, 2004, we completed a private placement equity offering that resulted in approximately \$12,000,000 in gross proceeds. Based on available cash resources, and projected revenue, we believe our existing financial resources will now be sufficient to sustain operations for at least the next

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

twenty-four (24) months. Our long-term viability and growth will depend upon the successful commercialization of our technologies and our ability to continue to obtain adequate financing, among other matters, as to which there can be no assurances.

15

RESULTS OF OPERATIONS

ON MARCH 30, 2004, WE COMPLETED THE ACQUISITION OF PSG WHICH NOW OPERATES AS OUR LAW ENFORCEMENT AND PUBLIC SAFETY DIVISION. THE DISCUSSION BELOW REGARDING OUR RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2004 REFLECTS THE COMBINED OPERATIONS OF OUR HISTORIC BIOMETRIC TECHNOLOGY LICENSING BUSINESS AND OUR NEW PUBLIC SAFETY DIVISION, WHEREAS THE CORRESPONDING PERIODS IN 2003 INCLUDE ONLY THE OPERATIONS OF OUR HISTORIC BIOMETRIC BUSINESS. IN ORDER TO PRESENT THE FOLLOWING DISCUSSION IN A MANNER TO PROVIDE A MORE MEANINGFUL COMPARISON BETWEEN THE TWO PERIODS, WHERE POSSIBLE, WE HAVE QUANTIFIED THE MATERIAL CHANGES IN OUR RESULTS OF OPERATIONS WHICH ARE ATTRIBUTABLE TO THE OPERATIONS OF EACH OF OUR BUSINESSES.

THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2004 AS COMPARED TO THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2003

REVENUE

We generated revenue of approximately \$519,000 during the three month period ended June 30, 2004 as compared to approximately \$13,000 during the corresponding period in 2003. Of this amount, approximately \$128,000 was generated by our biometric technology business, representing an approximate \$115,000 increase over the corresponding period in 2003. This increase was due to an increased number of licensing arrangements, some of which have moved from evaluation to recurring run time licenses. PSG, our law enforcement and public safety division which we acquired on March 30, 2004, accounted for approximately \$391,000 of the remaining revenue during the three month period ended June 30, 2004.

We generated revenue of approximately \$831,000 during the six month period ended June 30, 2004 as compared to approximately \$41,000 during the corresponding period in 2003. Of this amount, approximately \$253,000 was generated by our biometric technology business, representing an approximate \$212,000 increase over the corresponding period in 2003. This increase was due to an increased number of licensing arrangements, some of which have moved from evaluation to recurring run time licenses. Our law enforcement and public safety division accounted for approximately \$578,000 of the remaining revenue during the six month period ended June 30, 2004.

Consolidated revenue during the six month period ended June 30, 2004 consisted of approximately \$580,000 from license fees, approximately \$120,000 from product sales and approximately \$131,000 from technical support services. We expect to continue to generate a majority of our revenue from license fees and the balance from technical support and product sales. As our evaluation customers move to run time licensing arrangements, we expect technical support fees to comprise a larger percentage of our consolidated revenue and provide increased recurring monthly revenue. We continue to expand our sales and marketing departments and expect to continue to add customers and increase revenue during 2004 in both our biometric and public safety divisions. We expect the majority of our consolidated revenue through the remainder of 2004 to continue to be generated by our public safety division.

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

COSTS AND OTHER EXPENSES

COST OF PRODUCTS AND SERVICES SOLD. Cost of products and services sold were approximately \$95,000 during the three month period ended June 30, 2004 as compared to approximately \$3,000 during the corresponding period in 2003. Of

16

this amount, approximately \$31,000 was attributed to sales by our biometric technology business, representing an approximate \$28,000 increase from the corresponding period. Approximately \$64,000 of the remaining cost of products sold, was attributed to our law enforcement and public safety division. As our revenue and customer base continues to grow, we expect these costs to continue to increase. Most initial sales by our law enforcement and public safety division involve the sale of a PDA, and most initial sales by our biometrics business involve the sale of a scanner. We expect cost of products on a consolidated basis to continue to increase and be split approximately equally between our public safety and biometric technology businesses. Although we generate a margin on such sales, our future earnings, if any, will depend primarily upon licensing and technical support fees.

Cost of products and services sold were approximately \$101,000 during the six month period ended June 30, 2004 as compared to approximately \$6,000 during the corresponding period in 2003. Of this amount, approximately \$37,000 was attributed to sales by our biometric technology business, representing an approximate \$31,000 increase from the corresponding period. Approximately \$64,000 of the remaining cost of products sold, was attributed to our law enforcement and public safety division.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES. Selling, general and administrative expenses increased approximately \$877,000 to approximately \$1,346,000 during the three months ended June 30, 2004 as compared to approximately \$469,000 during the corresponding period in 2003. Of this amount, approximately \$878,000 was incurred by our biometric technology business, representing approximately a \$409,000 increase over the corresponding period in 2003. Approximately \$468,000 of the remaining selling, general and administrative expenses were incurred by our law enforcement and public safety division.

Of the approximately \$877,000 increase in selling, general and administrative expenses during the three months ended June 30, 2004, approximately \$312,000 was related to increased sales and marketing activity, approximately \$169,000 was related to an increase in general administrative costs, approximately \$106,000 was related to an increase in costs for administrative personnel, and approximately \$290,000 was related to an increase in professional services incurred in connection with additional SEC filings and the audit of PSG. Although we continue to closely monitor expenses, we retained 5 additional employees in connection with our recent acquisition of PSG, and have expanded both our direct sales force, marketing and technology support departments. We expect continued increases in these functions during 2004 as we continue to focus on generating additional revenue and supporting our growing customer base. Accordingly, we expect selling, general and administrative expenses to continue to increase during 2004.

Selling, general and administrative expenses increased approximately \$1,130,000 to approximately \$2,167,000 during the six months ended June 30, 2004 as compared to approximately \$1,037,000 for the corresponding period in 2003. Of

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

this amount, approximately \$1,699,000 was incurred by our biometric technology business, representing an approximate \$662,000 increase over the corresponding period in 2003. The remaining increase approximately \$468,000 was incurred by our law enforcement and public safety division.

17

Of the approximate \$1,130,000 increase in selling, general and administrative expenses during the six months period ended June 30, 2004, approximately \$257,000 was due to an increase in sales and marketing costs as we continue to focus substantial resources to generating revenue, approximately \$141,000 was due to an increase in executive personnel costs, approximately \$356,000 was due to an increase in general administrative costs and approximately \$376,000 was related to an increase in professional services incurred in connection with additional SEC filings and the audit of PSG.

RESEARCH AND DEVELOPMENT. Research, development and engineering expenses increased approximately \$98,000 to approximately \$352,000 during the three months ended June 30, 2004 as compared to approximately \$254,000 during the corresponding period in 2003. Of this amount, approximately \$276,000 was incurred by our biometric technology business, representing an approximate \$22,000 increase over the corresponding period in 2003. The remaining increase of approximately \$76,000 was incurred by our law enforcement and public safety division. Of the approximate \$98,000 increase in research, development and engineering expenses approximately \$60,000 was related to an increase in general development expense, and approximately \$38,000 related to a increase in personnel costs. Having completed the development of our core technology, research and development expenses in 2004 will consist of enhancing existing software and reacting to customer feedback. We expect research and development costs to stabilize during 2004 and be incurred primarily by our biometrics business.

Research, development and engineering expenses increased approximately \$140,000 to approximately \$615,000 during the six months ended June 30, 2004 as compared to approximately 475,000 during the corresponding period in 2003. Of this amount, approximately \$539,000 was incurred by our biometric technology business, representing an approximate \$64,000 increase over the corresponding period in 2003. Approximately \$76,000 of the remaining increase was incurred by our law enforcement and public safety division. Of the approximate \$140,000 increase in research, development and engineering expenses approximately \$35,000 was related to a increase in general development expense, and approximately \$105,000 related to a increase in personnel costs.

INTEREST EXPENSE. Interest expense was approximately \$1,000 and \$137,000 during the three and six month periods ended June 30, 2004, respectively, as compared to approximately \$303,000 and \$594,000 during the corresponding periods in 2003, respectively. Substantially all of the interest expense was incurred by our biometric technology business. The decrease in interest expense during the three and six months ended June 30, 2004 was due to the decrease in long-term obligations. As of the date of this report, all term indebtedness has been converted into equity.

NET OPERATING LOSS CARRYFORWARDS. As of December 31, 2003, we had federal and Minnesota net operating loss carryforwards of approximately \$24,504,000 and \$12,406,000, respectively. The carryforwards expire between 2011 and 2023. Such net operating carryforwards will be limited due to the change in ownership of the Company that has occurred, as defined in the Internal Revenue Code.

LIQUIDITY AND CAPITAL RESOURCES

Net cash used in operating activities during the six months ended June 30, 2004 was approximately \$2,307,000 compared to approximately \$1,307,000 during the six months ended June 30, 2003. The primary use of cash for both years was to fund the net losses. Net cash used in investing activities for the six months ended June 30, 2004 was approximately \$6,541,000 compared to net cash used in investing activities of approximately \$8,000 for the corresponding period in 2003 and consisted primarily of \$5,887,500 invested in government bonds, \$498,937 invested in the acquisition of PSG, \$50,000 invested in Classifeye, and \$79,089 invested in capital equipment additions. Net cash provided by financing activities during the six months ended June 30, 2004 was approximately \$11,673,000 compared to approximately \$1,553,000 in the corresponding period in 2003 and consisted primarily of \$11,249,000 from sales of our common stock and approximately \$1,000,000 from long term borrowings. These amounts were offset approximately \$400,000 for a note repayment, approximately \$100,000 for repurchasing warrants, approximately 44,000 in repayment of advances from a shareholder, and approximately \$32,000 for other items.

Working capital increased approximately \$3,161,000 during the six months ended June 30, 2004 to approximately \$4,246,000 compared to approximately \$1,085,000 as of December 31, 2003. This increase was due to an approximate \$11,249,000 increase in cash as a result of the completion of our recent private placements of our equity securities. This amount was offset by the purchase of approximately \$5,888,000 of marketable debt securities classified as held-to-maturity securities. Pursuant to an available credit facility, we can access an amount equal to up to 90% of the current market value of such marketable debt securities at a cost of funds equal to or less than the effective interest earned on such securities.

Since January 7, 1993 (date of inception), our capital needs have been principally met through proceeds from the sale of equity and debt securities. We do not currently maintain a line of credit or term loan with any commercial bank or other financial institution except as described in the immediate preceding paragraph.

On October 31, 2003, we entered into an amendment to the January 27, 2003 note purchase agreement with the Shaar Fund Ltd. ("Investor") to provide up to \$2,500,000 of additional financing pursuant to the terms of a secured promissory note (the "Secured Note"). Of this amount, \$600,000 was advanced at closing and \$1,900,000 was funded between December 3, 2003 and March 29, 2004. The Secured Note was due October 1, 2005, secured by substantially all of our assets including our intellectual property, accrued interest at the rate of 7% per annum payable on maturity, and may be prepaid without penalty. The principal amount and accrued interest was convertible at the option of the Investor into either shares of our common stock at a conversion price of \$.75 per share or shares of our series C preferred stock (the "Series C Shares") at a conversion price of \$100 per share. The Secured Note also provided that in the event we completed a private placement of our equity securities resulting in gross proceeds in excess of \$5,000,000 on or before June 30, 2004, some or all of the principal and accrued interest shall, at the option of the Investor, be either converted into such equity securities at a conversion price equal to the sale price of such securities or repaid in cash. Upon the closing of our recent private placement equity offering, the Investor elected to convert \$347,500 of the principal amount of the Secured Note into shares of our common stock and

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

warrants to purchase shares of our common stock, each issued to the Investor in connection with such private placement.

19

Pursuant to a recapitalization transaction completed on March 3, 2004, all existing promissory notes payable to the Investor, other than the Secured Note, together with all accrued and unpaid interest due thereon (approximately \$6,500,000) were cancelled and converted into 65,000 Series C Shares. Series C Shares are convertible into common stock at a conversion price of \$.75 per share. In the event that the trading price of our common stock is less than \$1.00 per share for thirty (30) consecutive days at any time after March 3, 2007, we will be required to redeem the Series C Shares at a redemption price of \$100 per share plus all accrued and unpaid dividends due thereon. In connection with the recapitalization transaction, the Investor transferred \$375,000 of the principal amount of the Secured Note to Thomas J. Colatosti, our Chairman of the Board of Directors.

On March 30, 2004, the Investor elected to convert \$1,827,463 of principal and accrued interest due under the Secured Note into 18,275 Series C Shares. Also on March 30, 2004, the Investor elected to exchange all of the issued and outstanding shares of our series B preferred stock and accrued and unpaid dividends thereon and all accrued and unpaid interest on such dividends into 5,257 additional Series C Shares. On April 29, 2004, Mr. Colatosti elected to convert \$375,000 of the principal amount of the Secured Note into 3,750 Series C Shares. As a result of these conversions, as of the date of this report, we have no outstanding indebtedness other than current liabilities.

Between April 7, 2004 and June 21, 2004, we issued an aggregate of 2,237,198 shares of common stock upon conversion of 16,600 shares of the Company's Series C 7% Convertible Preferred Stock and \$17,898 of dividends due thereon to the Shaar Fund.

On March 31, 2004, we entered into a securities purchase agreement with certain institutional and accredited investors pursuant to which we issued and sold an aggregate of 8,888,928 shares of our common stock and warrants (the "Warrants") to purchase an aggregate of 4,444,464 shares of our common stock. The investors paid an aggregate purchase price of \$1.35 for each share of common stock and Warrant to purchase 0.5 of a share of common stock, resulting in gross proceeds to of approximately \$12,000,000.

On March 30, 2004, we completed the acquisition of PSG in exchange for an aggregate of 2,416,108 shares of our common stock, \$500,000 in cash, and our assumption of \$600,000 in net liabilities of PSG. Any liability or obligation of PSG in excess of such \$600,000 limitation will be solely the responsibility of the former shareholders of PSG. In connection with this acquisition, we also issued 6,000 shares of our common stock to Harward Investments, Inc. ("Harward") pursuant to an arrangement involving the discharge of certain outstanding debt obligations of PSG to Harward as of March 30, 2004.

Additional earnout consideration, determined as a proportion of qualified revenues, as defined, attained by the acquired business during fiscal years 2004 and 2005, may be paid to the former shareholders of PSG. During 2004, earnout consideration, if any, will be paid at the following rates: Five percent (5%) of all 2004 Qualifying Revenue less than \$2 million, less the Accounts Receivable Holdback; as defined; Ten percent (10%) of all 2004 Qualifying Revenue equal to or greater than \$2 million but less than \$4 million; Twenty

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

percent (20%) of all 2004 Qualifying Revenue equal to or greater than \$4 million but less than \$7 million; and Thirty percent (30%) of all 2004 Qualifying Revenue equal to or greater than \$7 million. During 2005, earnout consideration, if any, will be paid at the following rates: Ten percent (10%) of all 2005

20

Qualifying Revenue equal to or greater than \$7 million but less than \$10 million; and Twenty percent (20%) of all 2005 Qualifying Revenue equal to or greater than \$10 million. We will make payments of such additional consideration on the last day of the month following each month in which the acquired business achieves specified revenue milestones during fiscal years 2004 and 2005. Such payments will be made in cash, unless the aggregate amount of earnout consideration exceeds sixty percent (60%) of the aggregate consideration we paid in the merger transaction. Any such excess amounts will be paid in shares of our common stock priced as of two (2) days prior to the date on which any earnout payment becomes due.

We recently announced, our intention to actively pursue strategic acquisitions that are expected to be accretive to operating results. We believe that an active acquisition strategy is timely because (i) companies with synergistic technology and/or market channels can combine to respond to the need in the homeland security market for complete technology solutions and to create operating efficiencies and (ii) there are many companies in the technology sector that have over-invested in the development stage and now lack sufficient financial resources to invest in the sales and marketing capabilities necessary for growth. To enable us to respond rapidly to acquisition opportunities, and to meet other future needs that could arise, we are seeking shareholder approval to increase the number of shares we are authorized to issue from 60 million to 85 million. While some of these newly authorized shares could be used as currency for acquisitions, we expect to raise the additional capital required for acquisitions through the issuance of convertible instruments that would not be immediately convertible into common stock. In that regard, we have engaged Jesup & Lamont, an investment banking firm, to assist us in reviewing potential acquisition candidates.

On August 16, 2004, we entered into a definitive agreement with Aether Systems, Inc. ("Aether") to purchase its Mobile Government Division for \$10 million in cash. It is anticipated that \$4.5 million in net working capital will be included in the assets and liabilities being conveyed, and that the acquisition will be financed using the Company's existing cash resources and new debt. In addition to the cash purchase price, the Company will either replace or secure the release of up to \$10.75 million of credit support arrangements that Aether currently has in place for its Mobile Government Division. Aether has agreed to accept a subordinated, secured note from the Company for up to \$8 million of this credit support if the Company cannot arrange to replace or release all of it by closing. The closing is expected to occur on or about September 30, 2004, and is subject to customary closing conditions.

Our future liquidity and capital requirements will depend upon numerous factors, including:

- o our ability to license our technology to original equipment manufacturers, systems integrators and application developers;
- o our ability to successfully integrate PSG's technology and

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

- customer relationships into our current business plan;
- o the costs and timing of product development efforts and the success of these efforts;
- o our ability to maintain and grow quality customer base; and
- o biometric technology market developments.

As of the date of this report, we had cash resources of approximately \$8,700,000 and no debt other than current liabilities. We currently require approximately \$400,000 per month to conduct our operations. During the first two quarters of 2004, we generated approximately \$831,000 of revenue and expect to continue to generate increasing revenue from existing and new relationships during 2004.

21

We now believe our current cash resources and anticipated cash flow from current operations will enable us to maintain operations at current levels for at least the next twenty-four (24) months. We may need to obtain additional funding to (i) conduct the sales, marketing and technical support necessary to execute our plan to substantially grow operations, increase revenue and serve a significant customer base; and (ii) pursue our acquisition strategy. While anticipated revenues are expected to defray operating expenses and reduce the need for additional financing, they are not expected to be sufficient for us to significantly expand operations. To the extent that we would require such additional funding, no assurance can be given that any form of additional financing will be available on terms acceptable to us, that adequate financing will be obtained to meet our needs, or that such financing would not be dilutive to existing stockholders. If available financing is insufficient or unavailable or we fail to continue to generate meaningful revenue, we may be required to further reduce operating expenses, delay the expansion of operations, or be unable to pursue merger or acquisition candidates.

ITEM 3. CONTROLS AND PROCEDURES

An evaluation of the effectiveness of the Company's "disclosure controls and procedures" (as such term is defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) was carried out by the Company under the supervision and with the participation of the Company's Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"). Based upon that evaluation, the Company's CEO and CFO concluded that, as of the end of the period covered by this quarterly report, the Company's disclosure controls and procedures were effective to provide reasonable assurance that information the Company is required to disclose in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms. There has been no change in the Company's internal control over financial reporting identified in connection with that evaluation that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II -- OTHER INFORMATION

ITEM 2. CHANGES IN SECURITIES AND SMALL BUSINESS ISSUER PURCHASES OF EQUITY SECURITIES

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

Between May 17 and June 21, 2004, we issued an aggregate of 611,019 shares of common stock upon conversion of 4,500 shares of the Company's Series C 7% Convertible Preferred Stock and \$8,264 of dividends due thereon to the Shaar Fund, Ltd. The shares were issued to one accredited investor in a private placement transaction exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 4(2) thereunder without payment of underwriting discounts or commissions to any person.

22

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) The following exhibits are included herein:

Exhibit No.	Exhibit	Method of Filing
2.1	Agreement and Plan of Merger dated as of March 30, 2004 by and among BIO-key International, Inc., BIO-Key Acquisition Corp., Public Safety Group, Inc. ("PSG") and each of the shareholders of PSG	Incorporated by reference to Ex the Registrant's Current Report dated March 30, 2004
3.1	Amended and Restated Articles of Incorporation	Incorporated by reference to Ex the Registrant's Registration S SB-2, File No. 333-16451 filed 1997 (the "Registration Stateme
3.2	Certificate of Amendment to Amended and Restated Articles of Incorporation	Incorporated by reference to Ex the Registrant's Report on Form the quarter ended March 31, 199
3.3	Amendment to the Amended and Restated Articles of Incorporation filed February 28, 2002	Incorporated by reference to Ex the Registrant's Registration S Form SB-2 filed March 27, 2002
3.4	Certificate of Designation of Series C Convertible Preferred Stock	Incorporated by reference to Ex the Registrant's Annual Report for the fiscal year ended Decem (the "2003 10-KSB")
3.5	Amended and Restated Bylaws	Incorporated by reference to Ex the Registration Statement
4.1	Specimen of Common Stock Certificate	Incorporated by reference to Ex the Registration Statement
10.1	SAC Technologies, Inc. 1996 Stock Option Plan	Incorporated by reference to Ex the Registration Statement
10.2	Amendment No. 1 to the SAC Technologies, Inc. 1996 Stock Option Plan	Incorporated by reference to Ex the 1999 10-KSB

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

10.3	SAC Technologies, Inc. 1999 Stock Option Plan	Incorporated by reference to Ex the 1999 10-KSB
10.4	Warrant issued to The Shaar Fund	Incorporated by reference to Ex the Registrant's Current Report dated November 26, 2001 (the "N 2001 8-K")
23		
10.5	Option to Purchase 150,000 Shares of Common Stock issued to Thomas J. Colatosti.	Incorporated by reference to Ex the Registrants Annual Report o for the fiscal year ended Decem (the "2002 10-KSB")
10.6	Non-Qualified Stock Option Agreement under the Registrant's 1999 Stock Incentive Plan to Purchase 200,000 Shares of Common Stock issued to Thomas J. Colatosti	Incorporated by reference to Ex the 2002 10-KSB
10.7	Employment Agreement by and between the Registrant and Michael W. DePasquale dated January 3, 2003	Incorporated by reference to Ex the 2002 10-KSB
10.8	Option to Purchase 580,000 Shares of Common Stock issued to Michael W. DePasquale	Incorporated by reference to Ex the 2002 10-KSB
10.9	Note Purchase Agreement dated January 27, 2003	Incorporated by reference to Ex the 2002 10-KSB
10.10	Secured Convertible Promissory Due June 30, 2004	Incorporated by reference to Ex the 2002 10-KSB
10.11	Option to Purchase 200,000 Shares of Common Stock issued to Charles P. Romeo	Incorporated by reference to Ex the 2002 10-KSB
10.12	Amendment No. 1 to Note Purchase Agreement dated October 31, 2003 by and between the Registrant and The Shaar Fund Ltd.	Incorporated by reference to Ex the 2003 10-KSB
10.13	Securities Exchange Agreement dated March 3, 2004 by and between the Registrant and The Shaar Fund Ltd.	Incorporated by reference to Ex the 2003 10-KSB
10.14	Registration Rights Agreement dated March 3, 2004 by and between the Registrant and The Shaar Fund Ltd.	Incorporated by reference to Ex the 2003 10-KSB
10.15	Secured Convertible Promissory Note due October 31, 2005 in the principal amount of up to \$2,125,000	Incorporated by reference to Ex the 2003 10-KSB
10.16	Secured Convertible Promissory Note due October 31, 2005 in the principal amount of \$375,000	Incorporated by reference to Ex the 2003 10-KSB

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

10.17	Option to Purchase 500,000 Shares of Common Stock issued to Michael W. DePasquale	Incorporated by reference to Ex the 2003 10-KSB

24		

10.18	Option to Purchase 150,000 Shares of Common Stock issued to Thomas J. Colatosti	Incorporated by reference to Ex the 2003 10-KSB
10.19	Option to Purchase 50,000 Shares of Common Stock issued to Thomas J. Colatosti	Incorporated by reference to Ex the 2003 10-KSB
10.20	Option to Purchase 50,000 Shares of Common Stock issued to Jeff May	Incorporated by reference to Ex the 2003 10-KSB
10.21	Option to Purchase 50,000 Shares of Common Stock issued to Charles Romeo	Incorporated by reference to Ex the 2003 10-KSB
10.22	Option to Purchase 300,000 Shares of Common Stock issued to Randy Fodero	Incorporated by reference to Ex the 2003 10-KSB
10.23	Amendment Agreement dated March 30, 2004 by and between the Registrant and The Shaar Fund Ltd.	Incorporated by reference to Ex the Registrant's Registration S Form SB-2 2004 File No. 333-115 April 30, 2004 (the "2004 Regis Statement")
10.24	Securities Purchase Agreement dated as of March 31, 2004 (the "Securities Purchase Agreement") by and among the Registrant and each of the Purchasers named therein.	Incorporated by reference to Ex the Registrant's current report filed with the Securities and E Commission on April 5, 2004 (th 2004 8-K")
10.25	Form of Warrant issued by BIO-key International, Inc. pursuant to the Securities Purchase Agreement	Incorporated by reference to Ex the April 5, 2004 8-K
31.1	Certificate of CEO of Registrant required by Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended	Filed herewith
31.2	Certificate of CFO of Registrant required by Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended	Filed herewith
32.1	Certificate of CEO of Registrant required by Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended	Filed herewith
32.2	Certificate of CFO of Registrant required by Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended	Filed herewith

(b) Current Reports on Form 8-K filed during the three month period ended June 30, 2004:

1. On April 5, 2004, the Company filed a Current Report on Form 8-K dated April 5, 2004, reporting under Item 5 the completion of a private placement of equity securities.

2. On April 14, 2004, the Company filed a Current Report on Form 8-K dated March 30, 2004, reporting under Item 2 the acquisition of Public Safety Group, Inc. On June 14, 2004, the Company filed Amendment No. 1 to Current Report on Form 8-K dated March 30, 2004, amending Item 7 thereof, to include the financial statements and pro forma financial information required thereby.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIO-KEY INTERNATIONAL, INC.

Edgar Filing: BIO KEY INTERNATIONAL INC - Form 10QSB

Dated: August 16, 2004

/s/ Michael W. DePasquale

Michael W. DePasquale
Chief Executive Officer

Dated: August 16, 2004

/s/ Gary Wendt

Gary Wendt
Chief Financial Officer

27

EXHIBIT INDEX

Exhibit No.	Exhibit	Method of Filing
31.1	Certificate of CEO of Registrant required by Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended	Filed herewith
31.2	Certificate of CFO of Registrant required by Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended	Filed herewith
32.1	Certificate of CEO of Registrant required by Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended	Filed herewith
32.2	Certificate of CFO of Registrant required by Rule 13a-14(b) under the Securities Exchange Act of 1934, as amended	Filed herewith

28